{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-043187","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.106731+00:00","generated_at":"2026-05-30T07:39:45.379026+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera reports Phase 3 sBCC study success; Ameluz-PDT primary endpoint met p<0.0001","bullets":["Primary endpoint: 65.5% complete clearance vs 4.8% placebo (p<0.0001); histological clearance 75.9% vs 19.0%.","Total clearance of all sBCC lesions: 64.1% vs 4.8% (p<0.0001); clinical clearance 83.4% vs 21.4%.","FDA dossier submission expected around end of Q2/early Q3 2025 after 12-month follow-up ends Dec 2024.","Study enrolled 187 patients; double-blind, randomized, placebo-controlled, multi-center design.","BCC is most common skin cancer in US (~3.6M cases/year); sBCC is a subset with limited non-invasive options."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-043187","json":"https://secwatch.observer/filing/0001493152-24-043187.json","markdown":"https://secwatch.observer/filing/0001493152-24-043187.md","text":"https://secwatch.observer/filing/0001493152-24-043187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224043187/0001493152-24-043187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224043187/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:39:45.379026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}